Back to "similar HRs for all-cause mortality (HR ..."
Claim
Strong Support
correlational
Analysis v3

Among adults with type 2 diabetes and advanced kidney disease, starting treatment with an SGLT2 inhibitor carries the same risk of serious heart problems or death as starting treatment with a GLP-1...

55
Pro
0
Against

Mechanism

Synthesis from 1 study

How it works

Both drugs lower blood pressure in the kidneys and reduce the heart's workload by removing excess sugar and salt. This protects the heart and blood vessels from damage, so neither drug has a clear advantage in preventing heart attacks, strokes, or death in people with advanced kidney disease and...

Most probable mechanism

In Simple Terms

Both drugs lower blood pressure in the kidneys and reduce the workload on the heart by decreasing sugar and salt retention, which protects the heart and blood vessels from damage over time.

Causal chain
1

SGLT2 inhibitors and GLP-1 receptor agonists both reduce tubular glucose reabsorption in the kidney, leading to osmotic diuresis and natriuresis

Supported by evidence
which leads to
2

This reduces intraglomerular pressure and renal hyperfiltration, lowering systemic blood pressure and cardiac afterload

Supported by evidence
which leads to
3

Both agents decrease circulating free fatty acids and improve myocardial energy efficiency by shifting substrate utilization toward ketone bodies and glucose

Supported by evidence
which leads to
4

Reduced metabolic stress and improved vascular function diminish endothelial dysfunction and arterial stiffness

Supported by evidence
which leads to
5

These combined effects stabilize cardiac output, reduce myocardial oxygen demand, and prevent progression of atherosclerosis and heart failure

Supported by evidence

Evidence from Studies

Supporting (1)

55

Community contributions welcome

55

Cardio-renal Outcomes in Type 2 Diabetes Patients with Advanced Chronic Kidney Disease on SGLT2 inhibitors or GLP-1 receptor agonists.

Cohort Study
Human
2026 Apr

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Sign up to see full verdict

Source Study

Cardio-renal Outcomes in Type 2 Diabetes Patients with Advanced Chronic Kidney Disease on SGLT2 inhibitors or GLP-1 receptor agonists.

Score: 55
DOI: 10.1016/j.amjmed.2025.12.011

Similar Assertions

Among adults with type 2 diabetes and advanced kidney disease, starting an SGLT2 inhibitor is linked to a 6% lower risk of heart failure than starting a GLP-1 receptor agonist, while the risks of major heart problems and death are the same with both drugs.

55
0
96%

Among adults with type 2 diabetes and advanced kidney disease, starting a GLP-1 receptor agonist is linked to a higher rate of serious kidney complications than starting an SGLT2 inhibitor, and this difference is larger in men and in people who do not already have heart failure.

55
0
96%

In adults with type 2 diabetes and advanced kidney disease, starting an SGLT2 inhibitor is linked to a 6% lower chance of developing heart failure than starting a GLP-1 receptor agonist, while the chances of major heart problems or death are the same with either drug.

55
0
96%

Among adults with type 2 diabetes and advanced kidney disease, starting an SGLT2 inhibitor instead of a GLP-1 receptor agonist is linked to a 5% lower risk of serious kidney complications, a 9% higher risk of needing dialysis, and no difference in heart events or death rates.

55
0
96%

In patients with type 2 diabetes and chronic kidney disease, GLP-1 receptor agonists do not significantly lower the risk of kidney-related complications compared to no treatment, based on a risk ratio of 0.90 with a confidence interval that includes no effect.

61
0
88%